Connect Biopharma Holdings Limited (CNTB) News
Filter CNTB News Items
CNTB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CNTB News Highlights
- CNTB's 30 day story count now stands at 3.
- Over the past 8 days, the trend for CNTB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CNTB are WEI.
Latest CNTB News From Around the Web
Below are the latest news stories about Connect Biopharma Holdings Ltd that investors may wish to consider to help them evaluate CNTB as an investment opportunity.
Connect Biopharma (CNTB) presents at SVB Leerink 11th Annual Global Healthcare Conference - SlideshowNo summary available. |
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare ConferenceSAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET. |
Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo —Analyses demonstrate that the benefits of CBP-201 to patients continue to increase as baseline disease severity increases — —Data and analyses support the potential for a highly competitive efficacy and safety profile for CBP-201 that includes a differentiated Q4W dosing schedule — SAN DIEGO, C |
Connect Biopharma''s Latest Dermatitis Drug Update Fails To Pump Up SharesNo summary available. |
Leerink Partners Thinks Connect Biopharma Holdings’ Stock is Going to RecoverIn a report released today, Thomas Smith from Leerink Partners maintained a Buy rating on Connect Biopharma Holdings (CNTB – Research Report), with a price target of $22.00. The company's shares closed last Wednesday at $5.00, close to its 52-week low of $4.10. According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.3% and a 21.4% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Eledon Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings. |
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis—Phase 2b trial previously reported achievement of both primary and key secondary end points, demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo— —Additional analyses demonstrate a potentially competitive therapeutic profile for CBP-201 300mg administered every two weeks (Q2W) or every four weeks (Q4W). Company to begin Phase 3 trial of CBP-201 in the second half of 2022— —Company management and Dr. Jonathan Silverberg, MD, PhD, MPH, will rev |
Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201SAN DIEGO and TAICANG, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will host a conference call and webcast to review detailed data from its global Phase 2b trial of CBP-201 in adult pat |
Federated Hermes Prudent Bear Fund Buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, ...Investment company Federated Hermes Prudent Bear Fund (Current Portfolio) buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, iShares MSCI Emerging Markets ETF, SPDR Biotech ETF, iShares MSCI EAFE ETF, sells S&P 500 ETF TRUST ETF, Financial Select Sector SPDR, Health Care Select Sector SPDR, ARK Genomic Revolution ETF, Cisco Systems Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Federated Hermes Prudent Bear Fund. |
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA CapitalIn this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […] |
Connect Biopharma hires new CFONo summary available. |